FOXM1 inhibitor RCM-1 (Robert Costa Memorial drug-1, RCM-1) is a small molecule potent inhibitor of FOXM1 transcription factor.
RCM-1 inhibited the nuclear localization of FOXM1 protein, increased its ubiquitination and caused degradation of FOXM1 in proteasome.
RCM-1 reduced airway resistance, increased lung compliance, and decreased proinflammatory cytokine production in mice exposed to the house dust mite and interleukin-13 (IL-13), which triggers goblet cell metaplasia.
RCM-1 reduced the formation and growth of tumor cell colonies in the colony formation assay.
In animal models, RCM-1 treatment inhibited growth of mouse rhabdomyosarcoma Rd76-9, melanoma B16-F10, and human H2122 lung adenocarcinoma.
RCM-1 decreased FOXM1 protein in the tumors, reduced tumor cell proliferation, and increased tumor cell apoptosis.
RCM-1 decreased protein levels and nuclear localization of β-catenin, and inhibited protein-protein interaction between β-catenin and FOXM1 in cultured tumor cells and in vivo.